Satkunanathan Stifani, Wheeler Jun, Thorpe Robin, Zhao Yuan
NIBSC/Medicines and Healthcare Products Regulatory Agency , Hertfordshire EN6 3QG, United Kingdom .
Hum Gene Ther. 2014 Nov;25(11):929-41. doi: 10.1089/hum.2014.041. Epub 2014 Sep 11.
Adeno-associated viral (AAV) vectors show great promise because of their excellent safety profile; however, pre-existing immune responses have necessitated the administration of high titer AAV, posing a significant challenge to the advancement of gene therapy involving AAV vectors. Recombinant AAV vectors contain minimum viral proteins necessary for their assembly and gene delivery functions. During the process of AAV assembly and production, AAV vectors acquire, inherently and submissively, various cellular proteins, but the identity of these proteins is poorly characterized. We reason that by identifying host cell proteins inherently associated with AAV vectors we may better understand the contribution of cellular components to AAV vector assembly and, ultimately, may improve the production of AAV vectors for gene therapy. In this study, three serotypes of recombinant AAV, namely AAV2, AAV5, and AAV8, were investigated. We used liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) methods to identify protein composition in purified AAV vectors, confirmed protein identities using western blotting, and explored the potential function of selected proteins in AAV vector production using small hairpin (shRNA) methods. Using LC-MS/MS, we identified 44 AAV-associated cellular proteins including Y-box binding protein (YB1). We showed for the first time that the establishment of a novel producer cell line by introducing an shRNA sequence down-regulating YB1 resulted in up to 45- and 9-fold increase in physical vector genome titers of AAV2 and AAV8, respectively, and up to 7-fold increase in AAV2 transduction vector genome titers. Our results revealed that YB1 gene knockdown promoted AAV2 rep expression and vector DNA production and reduced the number of empty particles in AAV2 products, suggesting that YB1 plays an important role in AAV vector assembly by competition with adenovirus E2A and AAV capsid proteins for binding to the inverted terminal repeat (ITR) sequence. The significance and implications of our findings in future improvement of AAV production are discussed.
腺相关病毒(AAV)载体因其出色的安全性而展现出巨大潜力;然而,预先存在的免疫反应使得必须给予高滴度的AAV,这对涉及AAV载体的基因治疗进展构成了重大挑战。重组AAV载体包含其组装和基因递送功能所需的最少病毒蛋白。在AAV组装和生产过程中,AAV载体自然且被动地获得各种细胞蛋白,但这些蛋白的特性却鲜为人知。我们推断,通过鉴定与AAV载体天然相关的宿主细胞蛋白,我们或许能更好地理解细胞成分对AAV载体组装的贡献,并最终可能改善用于基因治疗的AAV载体的生产。在本研究中,对三种重组AAV血清型,即AAV2、AAV5和AAV8进行了研究。我们使用液相色谱 - 质谱/质谱(LC - MS/MS)方法鉴定纯化的AAV载体中的蛋白质组成,通过蛋白质印迹法确认蛋白质身份,并使用小发夹(shRNA)方法探索所选蛋白质在AAV载体生产中的潜在功能。使用LC - MS/MS,我们鉴定出44种与AAV相关的细胞蛋白,包括Y盒结合蛋白(YB1)。我们首次表明,通过引入下调YB1的shRNA序列建立新型生产细胞系,可使AAV2和AAV8的物理载体基因组滴度分别提高多达45倍和9倍,AAV2转导载体基因组滴度提高多达7倍。我们的结果表明,YB1基因敲低促进了AAV2 rep表达和载体DNA产生,并减少了AAV2产物中空颗粒的数量,这表明YB1通过与腺病毒E2A和AAV衣壳蛋白竞争结合反向末端重复(ITR)序列,在AAV载体组装中发挥重要作用。讨论了我们的发现对未来AAV生产改进的意义和影响。